IQ-AI Limited (LON: IQAI) has entered into a global distribution partnership with AI Metrics, LLC.
- The company has stated that the agreement grants it non-exclusive global rights to market and distribute AI Metrics' liver surface nodularity (LSN) image analysis product.
- LSN is a first-to-market platform designed by AI Metrics as a virtual liver biopsy, evaluating it to assess Chronic Liver Disease (CLD) using commonly acquired CT images.
- The company has also offered its regulatory expertise and is assisting AI Metrics in obtaining CE Mark and FDA 510(k) market clearance in Europe and the U.S., respectively.
- On 9th January 2020, at the time of writing, GMT 08:01 AM, IQAI shares were trading at GBX 5.05, up by 0.25 points or 5.21% against the previous day closing price.